Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years with Non-Valvular Atrial Fibrillation

Dabigatran has been shown to be superior to warfarin for stroke prevention in non-valvular atrial fibrillation (NVAF) but with higher out-of-pocket costs for patients. Although dabigatran has been shown to be cost-effective from a societal perspective, cost implications for individual patients and i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Med Econ
Hlavní autoři: Salata, Brian M, Hutton, David W, Levine, Deborah A, Froehlich, James B, Barnes, Geoffrey D
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4627374/
https://ncbi.nlm.nih.gov/pubmed/23621506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3111/13696998.2013.800523
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky